The Thomson Reuters Pharma Knowledge Hub is an essential online repository of industry facts, trends and analysis. In one place, we’ve gathered the information that can help you enhance your discovery and development activities, and arm your decision-making.
Objectively identifying key opinion leaders (KOLs), scientific experts or clinical investigators to collaborate with can be an onerous task.
Thomson Reuters discusses the regulatory aspects of the KOL / industry relationship, proposes a primary means of determining KOL relevance, discusses methods for identifying KOLs to suit your business strategy, and proposes a solution for optimal KOL identification and selection.
Download our white paper, Key Opinion Leader Identification and Selection, to receive your complimentary copy.
Thomson Reuters believes that biomarkers will become one of the major driving forces of pharmaceutical research and drug development in the coming years.
- Receive the latest Biomarkers White Paper: Biomarkers: An indispensable addition to the drug development toolkit
- Biomarkers, Drug Development and the Advent of Personalized Medicine Presented by Dr Jeffery Ross, Albany Medical College, New York.
OCTOBER - DECEMBER 2008
- Developing drugs is an investment in the future. This quarter we focus on the greatest innovation in the pharmaceutical pipeline, from the launch of promising treatments such as Mozobil™ to phase-changing candidates such as Gene Signal’s GS-101. The Ones to Watch
- Each quarter, Thomson Reuters assesses the quantity and quality of the scientific materials published in the pharmaceutical industry. Between October and December 2008, Novartis made the biggest impact. Our report also summarizes our findings for the whole of the year. Who’s Making the Biggest Splash?
- During the fourth quarter of 2008, US-based companies topped our list of final ANDA approvals. We also profile the most interesting movements in the generics industry, focusing on Akorn-Strides, Anchen Pharmaceuticals and Cypress Pharmaceutical Inc. Movers & Shakers
- See the trends in global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output over the last 10 years.
We show how the pharmaceutical industry is already beginning to rely on biomarker information, and explain how important it is to establish the standards that will support increasing biomarker implementation in the future. Subscribe
In this white paper, we explore the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents. The potential of biomarkers to improve decision making, accelerate drug development and reduce development costs is discussed with insight from experts in industry and academia. Subscribe
Objectively identifying key opinion leaders (KOLs), scientific experts or clinical investigators to collaborate with can be an onerous task. Thomson Reuters discusses the regulatory aspects of the KOL / industry relationship, proposes a primary means of determining KOL relevance, discusses methods for identifying KOLs to suit your business strategy, and proposes a solution for optimal KOL identification and selection. Subscribe
The role of every brand manager, regardless of industry, is to ensure their company’s voice is heard over the background noise of the marketplace. Unlike other industries, however, guaranteeing a positive reception for a new pharmaceutical product isn’t just a case of spending the most on advertising or sponsorship. There are strategies you must adopt in order to influence the market positively and make sure you realize the greatest possible return on your investment. Download
Download your free slides today!
What are our experts saying?
